The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

JPMorgan raised the firm’s price target on Sanofi (SNY) to EUR 110 from EUR 105 and keeps a Neutral rating on the shares.Maximize Your ...

Sanofi's SNY -1.06% + Free Alerts short percent of float has fallen 8.33% since its last report. The company recently ...

Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.

Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by ...